Build Your Comparison

Side-by-side financial analysis
WHWK logo
WHWK
NRXP logo
NRXP
KO logo
KO
AXSM logo
AXSM
ATAI logo
ATAI
Try popular comparisons:

Stock Comparison

WHWK vs NRXP vs KO vs AXSM vs ATAI

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
WHWK
Whitehawk Therapeutics Inc

Biotechnology

HealthcareNASDAQ • US
Market Cap$206M
5Y Perf.-83.6%
NRXP
NRx Pharmaceuticals, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$66M
5Y Perf.-96.7%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+52.7%
AXSM
Axsome Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$13.13B
5Y Perf.+278.3%
ATAI
Atai Beckley N.V

Medical - Pharmaceuticals

HealthcareNASDAQ • NL
Market Cap$1.44B
5Y Perf.-78.8%

WHWK vs NRXP vs KO vs AXSM vs ATAI — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
WHWK logoWHWK
NRXP logoNRXP
KO logoKO
AXSM logoAXSM
ATAI logoATAI
IndustryBiotechnologyBiotechnologyBeverages - Non-AlcoholicBiotechnologyMedical - Pharmaceuticals
Market Cap$206M$66M$355.61B$13.13B$1.44B
Revenue (TTM)$7M$2M$49.28B$708M$3M
Net Income (TTM)$-21M$-25M$13.70B$-188M$-663M
Gross Margin89.3%37.1%61.7%92.6%82.0%
Operating Margin-16.0%-7.5%29.3%-24.8%-36.6%
Forward P/E25.3x
Total Debt$0.00$631K$45.49B$241M$2M
Cash & Equiv.$38M$8M$10.27B$323M$85M

WHWK vs NRXP vs KO vs AXSM vs ATAILong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

WHWK
NRXP
KO
AXSM
ATAI
StockJun 21Jun 26Return
Whitehawk Therapeut… (WHWK)10016.4-83.6%
NRx Pharmaceuticals… (NRXP)1003.3-96.7%
The Coca-Cola Compa… (KO)100152.7+52.7%
Axsome Therapeutics… (AXSM)100378.3+278.3%
Atai Beckley N.V (ATAI)10021.2-78.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: WHWK vs NRXP vs KO vs AXSM vs ATAI

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: KO leads in 3 of 6 categories (5-stock set), making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. Axsome Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. ATAI also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇KO emerged as the overall leader. Track its performance:
WHWK
Whitehawk Therapeutics Inc
The Income Pick

WHWK is the clearest fit if your priority is income & stability.

  • Dividend streak 1 yrs, beta 1.68
Best for: income & stability
NRXP
NRx Pharmaceuticals, Inc.
The Healthcare Pick

Among these 5 stocks, NRXP doesn't own a clear edge in any measured category.

Best for: healthcare exposure
KO
The Coca-Cola Company
The Quality Compounder

KO carries the broadest edge in this set and is the clearest fit for quality and dividends.

  • 27.8% margin vs ATAI's -190.2%
  • 2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend
  • 13.1% ROA vs ATAI's -264.2%, ROIC 15.8% vs -57.0%
Best for: quality and dividends
AXSM
Axsome Therapeutics, Inc.
The Long-Run Compounder

AXSM is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 35.5% 10Y total return vs KO's 121.1%
  • Beta 0.63 vs NRXP's 2.05
  • +140.2% vs NRXP's +11.6%
Best for: long-term compounding
ATAI
Atai Beckley N.V
The Growth Play

ATAI ranks third and is worth considering specifically for growth exposure and sleep-well-at-night.

  • Rev growth 12.3%, EPS growth -212.9%, 3Y rev CAGR 159.9%
  • Lower volatility, beta 1.61, Low D/E 0.9%, current ratio 11.74x
  • Beta 1.61, current ratio 11.74x
  • 12.3% revenue growth vs WHWK's -72.5%
Best for: growth exposure and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthATAI logoATAI12.3% revenue growth vs WHWK's -72.5%
Quality / MarginsKO logoKO27.8% margin vs ATAI's -190.2%
Stability / SafetyAXSM logoAXSMBeta 0.63 vs NRXP's 2.05
DividendsKO logoKO2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)AXSM logoAXSM+140.2% vs NRXP's +11.6%
Efficiency (ROA)KO logoKO13.1% ROA vs ATAI's -264.2%, ROIC 15.8% vs -57.0%

WHWK vs NRXP vs KO vs AXSM vs ATAI — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
WHWKWhitehawk Therapeutics Inc
FY 2025
Product
100.0%$7M
NRXPNRx Pharmaceuticals, Inc.
FY 2025
Therapy
100.0%$854,000
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B
AXSMAxsome Therapeutics, Inc.
FY 2025
Product
100.0%$634M
ATAIAtai Beckley N.V
FY 2024
Research And Development Services
100.0%$300,000

WHWK vs NRXP vs KO vs AXSM vs ATAI — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGATAI

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 3 of 6 comparable metrics.

KO is the larger business by revenue, generating $49.3B annually — 21493.2x NRXP's $2M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to ATAI's -190.2%. On growth, AXSM holds the edge at +57.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricWHWK logoWHWKWhitehawk Therape…NRXP logoNRXPNRx Pharmaceutica…KO logoKOThe Coca-Cola Com…AXSM logoAXSMAxsome Therapeuti…ATAI logoATAIAtai Beckley N.V
RevenueTrailing 12 months$7M$2M$49.3B$708M$3M
EBITDAEarnings before interest/tax-$114M-$31M$15.5B-$167M-$127M
Net IncomeAfter-tax profit-$21M-$25M$13.7B-$188M-$663M
Free Cash FlowCash after capex-$98M-$15M$12.6B-$71M-$117M
Gross MarginGross profit ÷ Revenue+89.3%+37.1%+61.7%+92.6%+82.0%
Operating MarginEBIT ÷ Revenue-16.0%-7.5%+29.3%-24.8%-36.6%
Net MarginNet income ÷ Revenue-2.9%-10.7%+27.8%-26.6%-190.2%
FCF MarginFCF ÷ Revenue-13.7%-6.5%+25.5%-10.0%-33.6%
Rev. Growth (YoY)Latest quarter vs prior year-100.0%+12.1%+57.4%-38.6%
EPS Growth (YoY)Latest quarter vs prior year+49.3%+87.0%+18.2%-3.3%+13.3%
KO leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — WHWK and KO and AXSM each lead in 1 of 3 comparable metrics.
MetricWHWK logoWHWKWhitehawk Therape…NRXP logoNRXPNRx Pharmaceutica…KO logoKOThe Coca-Cola Com…AXSM logoAXSMAxsome Therapeuti…ATAI logoATAIAtai Beckley N.V
Market CapShares × price$206M$66M$355.6B$13.1B$1.4B
Enterprise ValueMkt cap + debt − cash$168M$59M$390.8B$13.0B$1.4B
Trailing P/EPrice ÷ TTM EPS-12.61x-2.87x27.18x-69.34x-1.35x
Forward P/EPrice ÷ next-FY EPS est.25.27x
PEG RatioP/E ÷ EPS growth rate2.43x
EV / EBITDAEnterprise value multiple26.39x
Price / SalesMarket cap ÷ Revenue28.79x54.19x7.42x20.57x352.95x
Price / BookPrice ÷ Book value/share1.89x10.40x143.77x4.00x
Price / FCFMarket cap ÷ FCF67.15x
Evenly matched — WHWK and KO and AXSM each lead in 1 of 3 comparable metrics.

Profitability & Efficiency

KO leads this category, winning 6 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-4 for ATAI. ATAI carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to AXSM's 2.73x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs WHWK's 3/9, reflecting strong financial health.

MetricWHWK logoWHWKWhitehawk Therape…NRXP logoNRXPNRx Pharmaceutica…KO logoKOThe Coca-Cola Com…AXSM logoAXSMAxsome Therapeuti…ATAI logoATAIAtai Beckley N.V
ROE (TTM)Return on equity-12.0%+41.1%-2.6%-3.7%
ROA (TTM)Return on assets-11.2%-2.2%+13.1%-27.8%-2.6%
ROICReturn on invested capital-139.1%+15.8%-19.1%-57.0%
ROCEReturn on capital employed-120.7%+17.3%-52.1%-47.3%
Piotroski ScoreFundamental quality 0–936745
Debt / EquityFinancial leverage1.33x2.73x0.01x
Net DebtTotal debt minus cash-$38M-$7M$35.2B-$82M-$83M
Cash & Equiv.Liquid assets$38M$8M$10.3B$323M$85M
Total DebtShort + long-term debt$0$631,000$45.5B$241M$2M
Interest CoverageEBIT ÷ Interest expense-34.34x10.70x-34.13x-483.30x
KO leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

AXSM leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in AXSM five years ago would be worth $37,792 today (with dividends reinvested), compared to $213 for NRXP. Over the past 12 months, AXSM leads with a +140.2% total return vs NRXP's +11.6%. The 3-year compound annual growth rate (CAGR) favors AXSM at 50.5% vs WHWK's -19.1% — a key indicator of consistent wealth creation.

MetricWHWK logoWHWKWhitehawk Therape…NRXP logoNRXPNRx Pharmaceutica…KO logoKOThe Coca-Cola Com…AXSM logoAXSMAxsome Therapeuti…ATAI logoATAIAtai Beckley N.V
YTD ReturnYear-to-date+70.5%+46.6%+20.3%+42.8%+1.3%
1-Year ReturnPast 12 months+103.9%+11.6%+17.2%+140.2%+79.8%
3-Year ReturnCumulative with dividends-47.1%-28.2%+47.0%+241.0%+121.5%
5-Year ReturnCumulative with dividends-86.0%-97.9%+65.6%+277.9%-80.3%
10-Year ReturnCumulative with dividends-95.4%-96.0%+121.1%+3550.5%-48.2%
CAGR (3Y)Annualised 3-year return-19.1%-10.5%+13.7%+50.5%+30.3%
AXSM leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — KO and AXSM each lead in 1 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than NRXP's 2.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AXSM currently trades 98.9% from its 52-week high vs ATAI's 58.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricWHWK logoWHWKWhitehawk Therape…NRXP logoNRXPNRx Pharmaceutica…KO logoKOThe Coca-Cola Com…AXSM logoAXSMAxsome Therapeuti…ATAI logoATAIAtai Beckley N.V
Beta (5Y)Sensitivity to S&P 5001.68x2.05x-0.20x0.63x1.61x
52-Week HighHighest price in past year$5.50$5.05$84.04$257.93$6.75
52-Week LowLowest price in past year$1.57$1.62$65.35$96.09$2.00
% of 52W HighCurrent price vs 52-week peak+75.7%+76.0%+98.3%+98.9%+58.1%
RSI (14)Momentum oscillator 0–10045.555.160.673.639.4
Avg Volume (50D)Average daily shares traded331K1.3M12.7M690K5.9M
Evenly matched — KO and AXSM each lead in 1 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 1 of 1 comparable metric.

Analyst consensus: KO as "Buy", AXSM as "Buy", ATAI as "Buy". Consensus price targets imply 206.1% upside for ATAI (target: $12) vs 2.8% for AXSM (target: $262). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.

MetricWHWK logoWHWKWhitehawk Therape…NRXP logoNRXPNRx Pharmaceutica…KO logoKOThe Coca-Cola Com…AXSM logoAXSMAxsome Therapeuti…ATAI logoATAIAtai Beckley N.V
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$7.00$86.13$262.38$12.00
# AnalystsCovering analysts48254
Dividend YieldAnnual dividend ÷ price+2.5%
Dividend StreakConsecutive years of raises1560
Dividend / ShareAnnual DPS$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.2%0.0%0.0%
KO leads this category, winning 1 of 1 comparable metric.
Key Takeaway

KO leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AXSM leads in 1 (Total Returns). 2 tied.

Best OverallThe Coca-Cola Company (KO)Leads 3 of 6 categories
Loading custom metrics...

WHWK vs NRXP vs KO vs AXSM vs ATAI: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is WHWK or NRXP or KO or AXSM or ATAI a better buy right now?

For growth investors, Atai Beckley N.

V (ATAI) is the stronger pick with 1228% revenue growth year-over-year, versus -72. 5% for Whitehawk Therapeutics Inc (WHWK). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate The Coca-Cola Company (KO) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — WHWK or NRXP or KO or AXSM or ATAI?

Over the past 5 years, Axsome Therapeutics, Inc.

(AXSM) delivered a total return of +277. 9%, compared to -97. 9% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: AXSM returned +35. 5% versus NRXP's -96. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — WHWK or NRXP or KO or AXSM or ATAI?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus NRx Pharmaceuticals, Inc. 's 2. 05β — meaning NRXP is approximately -1122% more volatile than KO relative to the S&P 500. On balance sheet safety, Atai Beckley N. V (ATAI) carries a lower debt/equity ratio of 1% versus 3% for Axsome Therapeutics, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — WHWK or NRXP or KO or AXSM or ATAI?

By revenue growth (latest reported year), Atai Beckley N.

V (ATAI) is pulling ahead at 1228% versus -72. 5% for Whitehawk Therapeutics Inc (WHWK). On earnings-per-share growth, the picture is similar: Whitehawk Therapeutics Inc grew EPS 86. 0% year-over-year, compared to -212. 9% for Atai Beckley N. V. Over a 3-year CAGR, ATAI leads at 159. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — WHWK or NRXP or KO or AXSM or ATAI?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -161. 4% for Atai Beckley N. V — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -24. 4% for ATAI. At the gross margin level — before operating expenses — AXSM leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is WHWK or NRXP or KO or AXSM or ATAI more undervalued right now?

Analyst consensus price targets imply the most upside for ATAI: 206.

1% to $12. 00.

07

Which pays a better dividend — WHWK or NRXP or KO or AXSM or ATAI?

In this comparison, KO (2.

5% yield) pays a dividend. WHWK, NRXP, AXSM, ATAI do not pay a meaningful dividend and should not be held primarily for income.

08

Is WHWK or NRXP or KO or AXSM or ATAI better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, NRXP: -96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between WHWK and NRXP and KO and AXSM and ATAI?

These companies operate in different sectors (WHWK (Healthcare) and NRXP (Healthcare) and KO (Consumer Defensive) and AXSM (Healthcare) and ATAI (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WHWK is a small-cap quality compounder stock; NRXP is a small-cap quality compounder stock; KO is a large-cap quality compounder stock; AXSM is a mid-cap high-growth stock; ATAI is a small-cap high-growth stock. KO pays a dividend while WHWK, NRXP, AXSM, ATAI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.